Atypical Complications of Graves’ Disease: A Case Report and Literature Review

Khaled Ahmed Baagar,1 Mashhood Ahmed Siddique,1 Shaimaa Ahmed Arroub,1 Ahmed Hamdi Ebrahim,2 and Amin Ahmed Jayyousi1

1Endocrine Department, Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar
2Emergency Department, Hamad Medical Corporation, Doha, P.O. Box 3050, Qatar

Correspondence should be addressed to Khaled Ahmed Baagar; kbaagar@hamad.qa

Received 14 December 2016; Accepted 13 February 2017; Published 28 February 2017

Academic Editor: Toshihiro Kita

Copyright © 2017 Khaled Ahmed Baagar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Graves’ disease (GD) may display uncommon manifestations. We report a patient with rare complications of GD and present a comprehensive literature review. A 35-year-old woman presented with a two-week history of dyspnea, palpitations, and edema. She had a raised jugular venous pressure, goiter, and exophthalmos. Laboratory tests showed pancytopenia, a raised alkaline phosphatase level, hyperbilirubinemia (mainly direct bilirubin), and hyperthyroidism [TSH: <0.01 mIU/L (reference values: 0.45–4.5), fT4: 54.69 pmol/L (reference values: 9.0–20.0), and fT3: >46.08 pmol/L (reference values: 2.6–5.7)]. Her thyroid uptake scan indicated GD. Echocardiography showed a high right ventricular systolic pressure: 60.16 mmHg. Lugol’s iodine, propranolol, cholestyramine, and dexamethasone were initiated. Hematologic investigations uncovered no reason for the pancytopenia; therefore, carbimazole was started. Workup for hepatic impairment and pulmonary hypertension (PH) was negative. The patient became euthyroid after 3 months. Leukocyte and platelet counts and bilirubin levels normalized, and her hemoglobin and alkaline phosphatase levels and right ventricular systolic pressure (52.64 mmHg) improved. This is the first reported single case of GD with the following three rare manifestations: pancytopenia, cholestatic liver injury, and PH with right-sided heart failure. With antithyroid drug treatment, pancytopenia should resolve with euthyroidism, but PH and liver injury may take several months to resolve.

1. Introduction

Graves’ disease (GD) is an autoimmune thyroid disease first described by Robert Graves in 1835 [1]. Patients with GD usually present with common manifestations such as palpitations, tremors, heat intolerance, and weight loss. However, some patients may present with unusual gastrointestinal, hematologic, neurologic, and cardiopulmonary complications [2]. We report a patient who presented to our institution with pancytopenia and pulmonary hypertension (PH) with right-sided heart failure and raised liver enzymes. She was found to have GD. Further, there was no other explanation for her manifestations as the workup failed to reveal any other pathologic conditions. The pathogenesis of these complications in patients with GD is not completely understood. However, the prognosis is good if the underlying hyperthyroidism is treated with antithyroid drugs (ATDs). In this review, we discuss the prevalence of each complication, possible mechanisms of their development in the context of GD, and the clinical course during treatment of the underlying hyperthyroidism.

2. Case Presentation

A 35-year-old woman presented to our emergency department with a two-week history of breathlessness, palpitations, and generalized edema. She had a history of having lost approximately 10 kg of weight over a 3-month period but had regained weight in the month before presentation. She had no chronic illness and was not on any medication(s). On examination, she looked tired, was afebrile, and had a blood pressure of 103/58 mmHg, pulse rate of 92/min, and a respiratory rate of 20/min. She had exophthalmos, a raised jugular venous pressure, a diffuse goiter with a positive bruit, and bilateral pedal edema extending to the thighs. She had a third heart sound and bilateral fine basal lung
crepitations. Her abdominal examination was unremarkable with no tenderness or organomegaly. An electrocardiogram showed a sinus rhythm with right bundle branch block and right ventricular strain.

Laboratory investigations (detailed in Table 1) showed pancytopenia; raised bilirubin (mainly direct bilirubin) and alkaline phosphatase (ALP); and normal creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels. Her thyroid functions were as follows: thyroid-stimulating hormone (TSH), <0.01 mIU/L (reference values: 0.45–4.5); FT4, 54.69 pmol/L (reference values: 9–20); FT3, >46.08 pmol/L (reference values: 2.6–5.7); and antithyroid peroxidase, >1000 U.

Echocardiography showed an ejection fraction of 50–55%, a right ventricular systolic pressure (RVSP) of 60.16 mmHg measured by Doppler, and severe tricuspid regurgitation. Therefore, a computed tomography pulmonary angiogram was performed; it was negative for pulmonary embolism. A thyroid uptake scan showed diffusely increased uptake, indicating GD, and ultrasound examination showed a diffuse goiter with no nodules. She was initially started on Lugol's iodine, 7 drops (8 mg/drop) every 8 hours, propranolol, 40 mg every 8 hours, dexamethasone, 1 mg every 8 hours, and cholestyramine, 4 grams every 6 hours, to control thyrotoxicosis and to prevent further worsening of the patient's complications which were suspected to be related to GD. Also, 2 doses of intravenous furosemide 40 mg were given on the first hospital day then it was discontinued and the basal lungs crepitations disappeared on the following day.

Workup did not reveal any specific reason other than GD for her pancytopenia, PH, and raised alkaline phosphatase (ALP) and bilirubin. Regarding the pancytopenia, a peripheral blood smear showed a moderate normocytic anemia with mild hypochromia; a few ovalocytes, burr cells, and schistocytes; and increased rouleaux formation. There was leukopenia with neutropenia, some toxic features, a few reactive lymphocytes, and minor platelet clumps. The reticulocyte count was 3.2% (reference values: 0.5–2.5%), erythrocyte sedimentation rate was 3 mm/h (reference values: 2–37), C-reactive protein was 9 mg/L (reference values: 0–5), and hemoglobin electrophoresis was normal. The levels of all the following parameters were normal: lactate dehydrogenase, 184 U/L (reference values: 135–214); haptoglobin, 95 mg/dL (reference values: 35–250); folate, 34.5 nmol/L (reference values: 4.0–45.3); and vitamin B12, 617 pmol/L (reference values: 133–675). Iron studies showed the following: iron, 5 μmol/L (reference values: 5.83–34.5); total iron binding capacity, 32 μmol/L (reference values: 45–80); iron saturation, 15% (reference values: 15–45); transferrin, 1.29 g/L (reference values: 2–3.6); and ferritin, 38 μg/L (reference values: 11–304). Coombs test and HIV serology were negative. Additional workup for cholestatic liver impairment, viral hepatitis serology, and antimitochondrial antibodies (AMA) were negative. The patient's abdominal ultrasound was unremarkable, with no hepatic or splenic enlargement. Further investigations for PH, rheumatoid factor, and antinuclear (ANA), anti-neutrophil cytoplasmic, anti-RO, anti-LA, anti-JO, anti-scleroderma 70, anti-RNP, and anti-smith antibodies were

|                  | Presentation | Next day | 2 weeks | 3 months |
|------------------|--------------|---------|---------|----------|
| TSH (mIU/L)     | <0.01        | <0.01   | <0.01   | <0.01    |
| FT4 (pmol/L)    | 54.69        | 23.99   | 6.6     |          |
| FT3 (pmol/L)    | >46.08       | 12.98   | 3.97    | 3.97     |
| WBC (×10⁹/L)    | 2.9          | 3.6     | 3.9     | 6.8      |
| Neutrophils (×10⁹/L) | 1.1        | 2.2     | 2.1     | 3.8      |
| Hemoglobin (g/L)| 84           | 96      | 87      | 111      |
| Hematocrit (%)  | 26.6         | 33.7    | 30.4    | 36.7     |
| MCV (femtoliter)| 83.1         | 91.9    | 92.3    | 89.1     |
| Platelets (×10⁹/L) | 113        | 143     | 211     | 285      |
| T. bilirubin (μmol/L) | 35.3    | 31.1    | 21.9    | 11.7     |
| D. bilirubin (μmol/L) | 27.4    | 23.2    | 17.6    | 7.3      |
| I. bilirubin (μmol/L) | 6.9      | 262     | 303     | 311      |
| ALP (U/L)       | 304          | 262     | 303     | 311      |
| GGT (U/L)       |              | 128     | 98      |          |
| ALT (U/L)       | 14           | 13      | 12      | 18       |
| AST (U/L)       | 24           | 25      | 16      | 26       |
| Albumin (g/L)   | 29           | 25      | 25      | 34       |
| Weight (kg)     | 96           |         |         |          |

TSH: thyroid-stimulating hormone (0.45–4.5 mIU/L), FT4: free T4 (9–20 pmol/L), FT3: free T3 (2.6–5.7 pmol/L), WBC: white blood cells (4–10 × 10⁹/L), neutrophils (2–7 × 10⁹/L), hemoglobin (120–150 g/L), hematocrit (36–46%), MCV: mean corpuscular volume (83–101 femtoliter), platelets (150–400 × 10⁹/L), T. bilirubin: total bilirubin (3.4–20.5 μmol/L), D. bilirubin: direct bilirubin (0–8.6 μmol/L), I. bilirubin: indirect bilirubin (0–3 μmol/L), ALP: alkaline phosphatase (40–150 U/L), GGT: gamma-glutamyl transferase (9–36 U/L), ALT: alanine aminotransferase (0–55 U/L), AST: aspartate aminotransferase (5–34 U/L), albumin (35–50 g/L).

Table 1: Laboratory investigations at presentation and in the 3 months following carbimazole treatment.
negative. Complements 3 (C3) and 4 (C4) were 110 mg/dL (reference values: 90–180) and 18.4 mg/dL (reference values: 10–40), respectively.

Bone marrow examination was not performed as the reticulocyte count was high and in the following two days of the initial treatment patient’s white blood cells and platelets improved; at that point carbimazole 60 mg/day was started. After six days, she was ready for discharge from hospital on the same dose of carbimazole and propranolol, and furosemide was added for the lower limbs edema.

Follow-up investigations nine days later showed improvement in white blood cell and platelet counts. In addition, the gamma-glutamyl transferase (GGT) level was high (128 U/L [normal: 9–36]).

Two months after her initial presentation, the lower limb edema had improved but had not resolved completely. A month later (3 months after presentation), the lower limb edema disappeared. Moreover, the clinical and laboratory features of hyperthyroidism resolved with carbimazole therapy, and her bilirubin level and white blood cell and platelet counts normalized; and her hemoglobin, ALP, and GGT levels improved. ALP isoenzymes were checked; the raised ALP level was mainly of hepatic origin. Repeat echocardiography showed improvement of RVSP (52.64 mmHg) measured by Doppler, with moderate tricuspid regurgitation.

3. Discussion

GD is caused by autoantibodies that stimulate TSH receptors in the thyroid gland; it is the most common cause of hyperthyroidism [3]. Our patient is the first reported case to have these three rare complications of GD: pancytopenia, cholestatic hepatic injury, and PH with right-sided heart failure.

3.1. Pancytopenia. It is rare for patients with GD to have pancytopenia; there are only a few documented reports in the literature [1, 4–9]. However, single lineage abnormalities (anemia, leukopenia, or thrombocytopenia) are more common in patients with hyperthyroidism (34%, 5.8%, and 3.3%, resp.) [5, 10]. Leukopenia with a relative lymphocytosis is not an uncommon blood abnormality in GD, named “Kocher’s blood picture.” [11]. There was no identifiable cause for this patient’s anemia and it was similar to an anemia of chronic disease, commonly called “GD anemia,” that affects 22% of patients with GD [12]. Bone marrow examination in patients with GD, although was not performed in our case, could show hypercellular [8], normocellular [1, 5, 6], or, very rarely, hypoplastic [4] changes.

Initially, thionamides were not used. We chose a more conservative approach to treatment in this patient with multiple complications, using alternatives such as Lugol’s solution and cholestyramine, as we did not want to aggravate her pancytopenia. The use of radioactive iodine at the time of presentation might have precipitated a thyroid storm [13]; thus, it was not considered. However, once the workup for pancytopenia showed no other causes and the neutrophil and platelet counts were improving, we initiated treatment with carbimazole. Generally, the use of thionamides is contraindicated in patients with a baseline neutrophil count <0.5 × 10⁹/L [13] and should be stopped if the neutrophil count drops after their initiation below 1.0 × 10⁹/L [14]. Thus, although ATDs can be used in patients with hyperthyroidism-associated pancytopenia, their use is recommended only after a full hematologic assessment has been performed, as ATDs carry a minimal risk of pancytopenia [15]. Dexamethasone was added to the initial management because of the severe thyrotoxic state of the patient with pancytopenia. However, the evidence for its use in this situation was weak, being derived from a previous case report [5].

The duration of hyperthyroidism related pancytopenia is variable, from 2 weeks [1] to several months [4]; it resolves only when the patient is euthyroid. Pancytopenia should resolve by the time euthyroidism is reestablished; if it does not, hematologic evaluation should be revisited. It was reported that a patient with GD-related pancytopenia started on methimazole showed no improvement despite becoming euthyroid; investigations revealed methimazole-associated aplastic anemia [8].

The pathogenesis of GD-related pancytopenia is not fully understood and different theories exist [1, 4, 5, 10], including the following: (i) high level of circulating thyroid hormones, resulting in ineffective hematopoiesis; (ii) shortened blood cell lifespan, either by immune destruction or by sequestration; (iii) autoimmune mechanisms, given the presence of antineutrophil and antiplatelet antibodies; and (iv) direct bone marrow toxicity, as excessive thyroid hormones may adversely affect the pluripotent stem cells.

The mechanism of pancytopenia is most likely multifactorial as no single theory could explain it completely. The association between GD and other autoimmune hematologic disorders that respond to ATDs (e.g., autoimmune hemolytic anemia, immune thrombocytopenic purpura, and Evans syndrome [6]) supports the autoimmune theory. However, pancytopenia has also been reported with other forms of hyperthyroidism that are not immunologically mediated, such as toxic multinodular goiter [10], toxic adenoma [16], and even levotyroxine overtreatment in a patient previously treated for GD [17].

3.2. Cholestatic Hepatic Injury. The hepatic derangement in patients with GD ranges from mild laboratory abnormalities without clinical features to overt hepatitis [18], with either hepatic or cholestatic injury [19]. Our patient had a cholestatic pattern of liver impairment with raised bilirubin (predominantly direct bilirubin), ALP, and GGT. After 3 months of carbimazole treatment with resolution of hyperthyroidism, ALP and GGT levels were better, and bilirubin normalized. Moreover, ANA and AMA were negative, thereby excluding concomitant autoimmune liver disease such as primary biliary cirrhosis. The patient had no clinical or ultrasonographic manifestations of hepatic congestion (i.e., hepatic tenderness and hepatomegaly); thus, this was excluded as a reason for cholestatic hepatic injury.

ALP is the commonest liver enzyme to be increased in hyperthyroid patients at diagnosis (25–64%) [20, 21]. In a study of 30 patients with GD [22], the reported increase in different liver enzymes was as follows: ALP (33%), ALT
(26%), GGT (24%), AST (17%), and total bilirubin (8%). The initial increase in ALP may originate from the liver, bone, or both, so it is important to check for GGT and bilirubin levels to diagnose cholestasis [21]. With treatment of hyperthyroidism, improvement of GGT has been reported while the ALP level was increasing, mainly from the bone [20]. The ALP level can take several months to normalize after euthyroidism is reestablished; this is because of increased osteoblast activity [20]. However, our patient’s ALP after three months of treatment was mainly of liver origin.

The possible mechanisms of liver injury in hyperthyroidism are as follows [22, 23]: (i) relative hypoxia due to increased oxygen demand while the splanchnic blood supply is unchanged, leading to liver impairment and cholestasis in the centrilobular hepatocytes; (ii) congestive heart failure; (iii) direct toxicity by high thyroid hormones, although this has not been confirmed; and (iv) associated autoimmune liver disease.

Treatment of hyperthyroidism in patients with raised liver enzymes is challenging, as ATDs are hepatotoxic (0.5%) [24]. Carbimazole and methimazole usually cause cholestasis while propylthiouracil usually causes hepatocyte damage by an idiosyncratic mechanism unrelated to the dose [19, 24]. Thus, it is advised to investigate for a concomitant liver disease; if the workup is negative, thionamides can be used with careful monitoring; otherwise it is better to use an alternative, such as radioactive iodine ablation or thyroidectomy [2].

### 3.3. Pulmonary Hypertension

The association between hyperthyroidism and PH was first described in 1950 [25]. PH can be found in patients with GD or nodular goiter with hyperthyroidism [26]. In one study, PH was the most common cardiac complication detected by echocardiography in hyperthyroid patients [27], with a reported prevalence of 36–65% [28, 29]. However, most cases are mild and asymptomatic and are not identified in daily practice [27].

At presentation, the patient had bilateral basal lung crepitations indicative of left ventricular compromise; this can occur with hyperthyroidism. However, the left ventricular dysfunction was mild; the crepitations disappeared on the second day of hospitalization and the ejection fraction was 50–55% on initial echocardiographic examination. On the other hand, the lower limb edema secondary to right-sided heart failure took 3 months to resolve, indicating that this was the main impairment of cardiac function.

Our patient demonstrated an improvement of her RVSP from 60.16 mmHg at presentation to 52.64 mmHg after 3 months of carbimazole with the resolution of hyperthyroidism state. The weight changes that the patient experienced were interesting, as she initially lost weight secondary to hyperthyroidism but then regained some weight because of the right-sided heart failure with resultant edema. Subsequently, once treatment for GD had been initiated, unlike other patients who often gain weight, our patient lost weight as her right heart failure and edema improved. Most cases of PH recover by the time euthyroidism is reestablished. In one report, 79.2% of patients had normal pulmonary artery pressures after 11–21 weeks of ATD treatment [27]. However, in other reports, 3–14 months were needed until normalization of PH occurred [30, 31].

Theories to explain the relationship between hyperthyroidism and PH [32, 33] include the following: (i) autoimmune-mediated endothelial remodeling; (ii) mechanical endothelial damage caused by the high cardiac output; (iii) accelerated metabolism of pulmonary vasodilators (nitric oxide and prostacyclin); (iv) inhibited metabolism of pulmonary vasoconstrictors (endothelin-1, serotonin, and thromboxane); and (v) enhanced pulmonary vascular response to catecholamines. It has been found that pulmonary artery systolic pressure has a significant linear correlation with thyroid-stimulating hormone receptor antibody, pulmonary vascular resistance, and cardiac output [28].

In a study by Marvisi et al. [26] the group of patients who received methimazole showed a more rapid improvement in PH than those who received partial thyroidectomy without pretreatment with methimazole or β-blockers; the difference in the pulmonary pressure drop was significant after 15 days, but not after 90 days, of treatment. The methimazole effect may be due to its ability to suppress Ng-nitro-l-arginine methyl ester production, which acutely inhibits nitric oxide synthesis, resulting in increased levels of nitric oxide [34]. In addition, methimazole might cause direct vasodilatation of the pulmonary vasculature [26]. The possibility of thyroid dysfunction should be considered in patients with unexplained PH, as long-standing untreated hyperthyroidism may lead to refractory PH [32, 35].

### 4. Conclusion

Patients with GD may present with rare manifestations that have partially understood mechanisms. With ATDs treatment, pancytopenia should resolve as euthyroidism is reestablished. Liver enzyme levels and PH may normalize, or at least show some improvement, once normal thyroid function is established, with full recovery several months later.

When treating patients with GD, it is generally recommended that liver function tests and a complete blood count be performed before initiating ATDs [13]. Having this baseline information gives insight about the abnormal laboratory findings primarily related to the hyperthyroid state, which is reversible with ATD treatment, and eliminates doubt around whether subsequent abnormal test results are secondary to the use of ATDs.

It is crucial to test the thyroid function of a patient presenting with any of the complications described in our patient where no clear explanation is found. Lack of awareness of such associations with GD may lead to misdiagnosis or delayed diagnosis, with a redundant workup being performed [2].

### Competing Interests

The authors declare that they have no competing interests.

### References

[1] A. N. Rafhati, C. K. See, F. K. Hoo, and L. B. Badrulnizam, "A report of three cases of untreated Graves’ disease associated with
pancytopenia in Malaysia,” Electronic Physician, vol. 6, no. 3, pp. 877–882, 2014.

[2] M. O. Hegazi and S. Ahmed, “Atypical clinical manifestations of Graves’ disease: an analysis in depth,” Journal of Thyroid Research, vol. 2012, Article ID 768019, 8 pages, 2012.

[3] J. A. Franklyn and K. Boelaert, “Thyrotoxicosis,” The Lancet, vol. 379, no. 9821, pp. 1155–1166, 2012.

[4] J. Garcia, L. D. França, V. Ellinger, and M. Wolff, “Marrow hypoplasia: a rare complication of untreated grave’s disease,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 58, no. 9, pp. 953–957, 2014.

[5] T. H. Kim, J. S. Yoon, B. S. Park et al., “A Case of pancytopenia with hyperthyroidism,” Yeungnam University Journal of Medicine, vol. 30, no. 1, pp. 47–50, 2013.

[6] P. Naji, G. Kumar, S. Dewani, W. A. Diedrich, and A. Gupta, ‘Grave’s disease causing pancytopenia and autoimmune hemolytic anemia at different time intervals: a case report and a review of the literature,” Case Reports in Medicine, vol. 2013, Article ID 194542, 4 pages, 2013.

[7] S. Raina, R. Kaul, and M. Murthyjunaya, “Pancytopenia with cellular bone marrow related to Graves’ hyperthyroidism,” Indian Journal of Endocrinology and Metabolism, vol. 16, no. 3, pp. 478–479, 2012.

[8] C. S. P. Lima, D. E. Zantut Wittmann, V. Castro et al., “Pancytopenia in untreated patients with Graves’ disease,” Thyroid, vol. 16, no. 4, pp. 403–409, 2006.

[9] L. Kebapçılar, S. Yesil, F. Bayraktar et al., “Recovery from pancytopenia and liver dysfunction after administration of propylthiouracil for Graves’ disease,” New Zealand Medical Journal, vol. 118, no. 1220, 2005.

[10] P. Jha, Y. P. P. Singh, B. Ghimire, and B. K. U. Jha, “Pancytopenia in a surgical patient, a rare presentation of hyperthyroidism,” BMC surgery, vol. 14, article 108, 2014.

[11] W. J. Irvine, F. C. W. Wu, S. J. Urbaniak, and F. Toolis, “Peripheral blood leucocytes in thyrotoxicosis (Graves’ disease) as studied by conventional light microscopy,” Clinical & Experimental Immunology, vol. 27, no. 2, pp. 216–221, 1977.

[12] A. G. Gianoukakis, M. J. Leigh, P. Richards et al., “Characterization of the anaemia associated with Graves’ disease,” Clinical Endocrinology, vol. 70, no. 5, pp. 781–787, 2009.

[13] R. S. Bahn, H. B. Burch, D. S. Cooper et al., “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and American association of clinical endocrinologists,” Endocrine Practice, vol. 17, no. 3, pp. 456–520, 2011.

[14] D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 352, no. 9, pp. 905–917, 2005.

[15] N. Watanabe, H. Narimatsu, J. Y. Noh et al., “Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. E49–E53, 2012.

[16] M. Duquenne, D. Lakomsy, J. C. Humbert, S. Hadjadj, G. Wer- yha, and J. Leclere, “Resolutive pancytopenia with effective treatment of hyperthyroidism,” Presse Medicale, vol. 24, no. 17, pp. 807–810, 1995.

[17] A. L. Talansky, P. Schulman, V. P. Vinciguerra, D. Margouleff, D. R. Budman, and T. J. Degnan, “Pancytopenia complicating Graves’ disease and drug-induced hypothyroidism,” Archives of Internal Medicine, vol. 141, no. 4, pp. 544–545, 1981.

[18] M. O. Hegazi and M. R. El-Sonbaty, “Unusual presentations of hyperthyroidism,” in Handbook of Hyperthyroidism: Etiology, Diagnosis and Treatment, L. Mertens and J. Bogaert, Eds., pp. 265–270, Nova Science Publishers, 2010.

[19] R. Malik and H. Hodgson, “The relationship between the thyroid gland and the liver,” The Quarterly Journal of Medicine, vol. 95, pp. 559–569, 2002.

[20] V. Sarinnapakorn, P. Noppaveetchich, T. Sunthorntrawarakul, C. Deerochanawong, and S. Ngomgamrutt, “Abnormal liver function test in Graves’ disease: a prospective study of comparison between the hyperthyroid state and the euthyroid state,” Journal of the Medical Association of Thailand, vol. 94, supplement 2, pp. S11–S16, 2011.

[21] G. R. Doran, “Serum enzyme disturbances in thyrotoxicosis and myxoedema,” Journal of the Royal Society of Medicine, vol. 71, no. 3, pp. 189–194, 1978.

[22] M. Biscoveanu and S. Hasinski, “Abnormal results of liver function tests in patients with Graves’ disease,” Endocrine Practice, vol. 6, no. 5, pp. 367–369, 2000.

[23] S. Khemichian and T.-L. Fong, “Hepatic dysfunction in hyperthyroidism,” Gastroenterology & Hepatology, vol. 7, no. 5, pp. 337–339, 2011.

[24] D. S. Cooper, “Hyperthyroidism,” The Lancet, vol. 362, no. 9382, pp. 459–468, 2003.

[25] J. D. Myers, E. S. Brannon, and B. C. Holland, “A correlative study of the cardiac output and the hepatic circulation in hyperthyroidism,” The Journal of Clinical Investigation, vol. 29, no. 8, pp. 1069–1077, 1950.

[26] M. Marvisi, P. Zambrelli, M. Brianti, G. Civardi, R. Lampugnani, and R. Delsignore, “Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy,” European Journal of Internal Medicine, vol. 17, no. 4, pp. 267–271, 2006.

[27] S. Muthukumar, D. Sadacharan, K. Ravikumar, G. Mohanapriya, Z. Hussain, and R. V. Suresh, “A prospective study on cardiovascular dysfunction in patients with hyperthyroidism and its reversal after surgical cure,” World Journal of Surgery, vol. 40, no. 3, pp. 622–628, 2016.

[28] T. Sugiura, S. Yamanaka, H. Takeuchi, N. Morimoto, M. Kamiska, and Y. Matsumura, “Autoimmunity and pulmonary hypertension in patients with Graves’ disease,” Heart and Vessels, vol. 30, no. 5, pp. 642–646, 2015.

[29] M. Armigliato, R. Paolini, S. Aggio et al., “Hyperthyroidism as a cause of pulmonary arterial hypertension: a prospective study,” Angiology, vol. 57, no. 5, pp. 600–606, 2006.

[30] I. A. Nakchbandi, J. A. Wirth, and S. E. Inzucchi, “Pulmonary hypertension caused by Graves’ thyrotoxicosis: normal pulmonary hemodynamics restored by 131I treatment,” Chest, vol. 116, no. 5, pp. 1483–1485, 1999.

[31] M. O. Hegazi, A. El Sayed, and H. El Ghoussein, “Pulmonary hypertension responding to hyperthyroidism treatment,” Respiriology, vol. 13, no. 6, pp. 923–925, 2008.

[32] A. Frogoudaki, A. S. Triantafyllis, E. Vasilatou, C. Tsamakis, A. Zacharoulis, and J. Lekakis, “Shortness of breath and lower limb edema in a 54-year-old woman, is there any cure?” Research in Cardiovascular Medicine, vol. 5, no. 1, Article ID e30549, 2015.

[33] B. Biondi and G. J. Kahaly, “Cardiovascular involvement in patients with different causes of hyperthyroidism,” Nature Reviews Endocrinology, vol. 6, no. 8, pp. 431–443, 2010.
[34] F. Vargas, A. Fernandez-Rivas, and A. Osuna, “Effects of methimazole in the early and established phases of \(\text{N}^6\)-nitro-L-arginine methyl ester hypertension,” *European Journal of Endocrinology*, vol. 135, no. 4, pp. 506–513, 1996.

[35] J. Y. Hwang, S. H. Bae, J. M. Lee et al., “A case of pulmonary arterial hypertension associated with hyperthyroidism, persistent after euthyroidism was obtained,” *Korean Circulation Journal*, vol. 40, no. 11, pp. 593–595, 2010.